Waverly Advisors LLC Sells 5,199 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

• Waverly Advisors reduced its Thermo Fisher Scientific holdings by 14.5%, selling 5,199 shares in the second quarter and retaining 30,634 shares valued at approximately $15.4 million. Institutional investors collectively own 89.23% of the company.
• Thermo Fisher reported stronger-than-expected quarterly results, with EPS of $6.03 and revenue of $11.99 billion, up 10.5% year over year. The company issued fiscal 2026 EPS guidance of $24.93–$25.33.
• Analyst sentiment remains favorable, with the stock carrying a consensus “Moderate Buy” rating and an average price target of $624.64; UBS upgraded the shares to “buy” with a $730 target. The company also declared a quarterly dividend of $0.47 per share.

Waverly Advisors LLC decreased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 14.5% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 30,634 shares of the medical research company's stock after selling 5,199 shares during the quarter. Waverly Advisors LLC's holdings in Thermo Fisher Scientific were worth $15,359,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Bank OZK bought a new position in Thermo Fisher Scientific during the second quarter worth $1,096,000. Ausdal Financial Partners Inc. bought a new position in Thermo Fisher Scientific during the 2nd quarter worth $456,000. North Dakota State Investment Board acquired a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth $7,505,000. BlackRock Inc. bought a new stake in shares of Thermo Fisher Scientific in the second quarter valued at about $15,501,867,000. Finally, German American Bancorp Inc. acquired a new position in shares of Thermo Fisher Scientific during the 2nd quarter worth approximately $4,920,000. 89.23% of the stock is currently owned by institutional investors.

Thermo Fisher Scientific Price Performance

Shares of NYSE TMO opened at $603.43 on Wednesday. The company has a current ratio of 1.55, a quick ratio of 1.18 and a debt-to-equity ratio of 0.74. Thermo Fisher Scientific Inc. has a 1-year low of $435.27 and a 1-year high of $647.00. The firm's 50-day moving average price is $575.12 and its 200-day moving average price is $516.59. The firm has a market capitalization of $223.12 billion, a P/E ratio of 32.46, a P/E/G ratio of 2.57 and a beta of 0.85.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, topping analysts' consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The company had revenue of $11.99 billion for the quarter, compared to analyst estimates of $11.71 billion. During the same period in the prior year, the firm earned $4.28 earnings per share. Thermo Fisher Scientific's revenue for the quarter was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 25.13 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be issued a dividend of $0.47 per share. The ex-dividend date is Tuesday, September 15th. This represents a $1.88 annualized dividend and a yield of 0.3%. Thermo Fisher Scientific's dividend payout ratio is 10.11%.

Insider Activity

In related news, EVP Michael Shafer sold 25,500 shares of the firm's stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $600.00, for a total transaction of $15,300,000.00. Following the transaction, the executive vice president directly owned 20,994 shares of the company's stock, valued at $12,596,400. This trade represents a 54.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Lisa Britt sold 11,440 shares of the stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $613.12, for a total transaction of $7,014,092.80. Following the completion of the sale, the vice president owned 14,784 shares of the company's stock, valued at approximately $9,064,366.08. This trade represents a 43.62% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 73,768 shares of company stock worth $44,122,820. Company insiders own 0.33% of the company's stock.

Analysts Set New Price Targets

Several research firms recently issued reports on TMO. UBS Group upgraded shares of Thermo Fisher Scientific from a "neutral" rating to a "buy" rating and set a $730.00 price target on the stock in a research report on Tuesday. Barclays boosted their price target on Thermo Fisher Scientific from $625.00 to $650.00 and gave the stock an "overweight" rating in a report on Friday, July 24th. Sanford C. Bernstein assumed coverage on shares of Thermo Fisher Scientific in a report on Friday, June 26th. They issued a "market perform" rating and a $520.00 price objective for the company. Wall Street Zen raised shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a report on Saturday, August 1st. Finally, Royal Bank Of Canada raised their target price on Thermo Fisher Scientific from $490.00 to $580.00 and gave the stock a "sector perform" rating in a research report on Friday, July 24th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $624.64.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc is a global supplier of scientific equipment, laboratory services and analytical technologies. The company serves pharmaceutical and biotechnology companies, clinical laboratories, academic and government institutions, industrial businesses and other research organizations.

Its products and services include laboratory instruments, analytical systems, reagents, consumables, software and related services. Thermo Fisher also provides laboratory supplies and equipment, bioproduction solutions, genetic analysis technologies, clinical diagnostics, specialty diagnostic products and contract research and manufacturing services through its laboratory services businesses.

The company was formed in 2006 through the merger of Thermo Electron Corporation and Fisher Scientific International.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.